Get the Stockscreener App
0.2432
2.72%
-0.0068
After Hours:
.24
-0.0032
-1.32%
Scisparc Ltd stock is traded at $0.2432, with a volume of 1.66M.
It is down -2.72% in the last 24 hours and down -32.46% over the past month.
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$0.25
Open:
$0.2564
24h Volume:
1.66M
Relative Volume:
0.49
Market Cap:
$2.62M
Revenue:
$2.88M
Net Income/Loss:
$-5.12M
P/E Ratio:
-0.000901
EPS:
-269.9888
Net Cash Flow:
-
1W Performance:
-7.88%
1M Performance:
-32.46%
6M Performance:
-86.26%
1Y Performance:
-93.05%
1-Day Range:
$0.241
$0.266
1-Week Range:
$0.234
$0.266
52-Week Range:
$0.234
$14.22
Scisparc Ltd Stock (SPRC) Company Profile
Scisparc Ltd Stock (SPRC) Latest News
SciSparc secures FDA approval to launch Phase IIB trial for TS treatment - TipRanks
FDA greenlights SciSparc's Phase IIb Tourette Syndrome study - Investing.com
SciSparc Secures FDA Green Light to US Launch of its - GlobeNewswire
Financial Metrics Check: SciSparc Ltd (SPRC)’s Ratios for Trailing Twelve Months - The Dwinnex
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - StockTitan
SciSparc Ltd (SPRC) stock: A year of ups and downs - US Post News
SciSparc signs LOI to sell entire ownership in MitoCareX - MSN
SciSparc Ltd. Proposes Reverse Stock Split - TipRanks
SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN
SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Canada
SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com
SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Australia
SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com India
SciSparc Announces Intent to Sell MitoCareX Stake - TipRanks
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - StockTitan
Holdings of SciSparc Ltd (SPRC) are aligned with the stars - SETE News
Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World
Smartgroup Announces Major Shareholding Changes - TipRanks
Science Group PLC Executes Share Buyback - TipRanks
Site Group Plans Massive New Share Issue - TipRanks
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World
Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily
SIGA Technologies (NASDAQ:SIGA) Shares Down 2.4% - MarketBeat
CSG urges Vista Outdoor stockholders to vote for $2.15B Kinetic Group deal - TipRanks
Smiths Group results: Could the share price sell-off present an opportunity? - Investors Chronicle
SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts
Clearmind, SciSparc slide amid weight-loss study results - MSN
FINANCIALS: SThree reports 8% drop due to challenging conditions - Recruiter
UBS Cuts Stake in Spirent Communications - TipRanks
SThree maintains expectations amid tough market conditions. - Research the market
UK recruiter SThree falls on lower Q3 net fee - XM
SThree says UK the worst performer as recruitment fees drop - Proactive Investors UK
Science Group PLC Announces Share Buyback - TipRanks
SThree plc Navigates Market Headwinds in Q3 - TipRanks
SThree Net Fees Fall Amid Challenging Environment - MarketWatch
Recruiter SThree holds guidance despite ‘challenging’ market conditions - City A.M.
100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World
SciSparc Ltd Inc. (SPRC) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat
Financial Survey: ScripsAmerica (OTCMKTS:SCRCQ) versus Cosmos Health (NASDAQ:COSM) - Defense World
Market Watch: SciSparc Ltd (SPRC)’s Noteworthy Drop, Closing at 0.26 - The Dwinnex
Barclays Ups Stake in Spirent Communications - TipRanks
FDA greenlights SciSparc's phase IIb trial for Tourette Syndrome - Investing.com
Are SciSparc Ltd’shares a good deal? - US Post News
SciSparc Advances Tourette Syndrome Drug Trial - TipRanks
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewswire
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - Marketscreener.com
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - EIN News
Avoro Capital Advisors LLC Purchases Shares of 1,839,138 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Sprout Social, Inc. (SPT): Short Seller Sentiment is Bearish on This AI Stock Under $50 - Insider Monkey
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):